New England Journal of Medicine · 202015,505 citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc +21 more
3discussions
Abstract
A randomized, placebo-controlled trial of the BNT162b2 mRNA vaccine in ~43,000 participants reported about 95% efficacy against symptomatic Covid-19 with a favorable short-term safety profile.